Equitable Trust’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.2M | Buy |
11,841
+1,879
| +19% | +$1.92M | 0.59% | 40 |
|
|
2026
Q1 | $9.16M | Sell |
9,962
-365
| -4% | -$370K | 0.42% | 53 |
|
|
2025
Q4 | $11.1M | Buy |
10,327
+2,325
| +29% | +$2.22M | 0.5% | 42 |
|
|
2025
Q3 | $6.11M | Sell |
8,002
-309
| -4% | -$230K | 0.28% | 68 |
|
|
2025
Q2 | $6.48M | Sell |
8,311
-112
| -1% | -$87K | 0.32% | 60 |
|
|
2025
Q1 | $6.96M | Sell |
8,423
-134
| -2% | -$112K | 0.39% | 51 |
|
|
2024
Q4 | $6.61M | Buy |
8,557
+17
| +0.2% | +$14.1K | 0.37% | 51 |
|
|
2024
Q3 | $7.57M | Buy |
8,540
+26
| +0.3% | +$23.4K | 0.49% | 41 |
|
|
2024
Q2 | $7.71M | Buy |
8,514
+1
| +0% | +$800 | 0.53% | 39 |
|
|
2024
Q1 | $6.62M | Sell |
8,513
-327
| -4% | -$233K | 0.46% | 45 |
|
|
2023
Q4 | $5.15M | Sell |
8,840
-60
| -0.7% | -$35K | 0.39% | 51 |
|
|
2023
Q3 | $4.78M | Buy |
8,900
+175
| +2% | +$90.2K | 0.4% | 51 |
|
|
2023
Q2 | $4.09M | Sell |
8,725
-215
| -2% | -$90.2K | 0.31% | 61 |
|
|
2023
Q1 | $3.07M | Buy |
8,940
+156
| +2% | +$52.6K | 0.24% | 80 |
|
|
2022
Q4 | $3.21M | Sell |
8,784
-1,079
| -11% | -$383K | 0.25% | 84 |
|
|
2022
Q3 | $3.19M | Sell |
9,863
-933
| -9% | -$296K | 0.27% | 83 |
|
|
2022
Q2 | $3.5M | Sell |
10,796
-605
| -5% | -$182K | 0.26% | 83 |
|
|
2022
Q1 | $3.27M | Sell |
11,401
-268
| -2% | -$69K | 0.21% | 101 |
|
|
2021
Q4 | $3.22M | Sell |
11,669
-87
| -0.7% | -$22.1K | 0.2% | 104 |
|
|
2021
Q3 | $2.72M | Sell |
11,756
-659
| -5% | -$163K | 0.17% | 115 |
|
|
2021
Q2 | $2.85M | Buy |
12,415
+308
| +3% | +$61.9K | 0.18% | 114 |
|
|
2021
Q1 | $2.26M | Buy |
12,107
+2,476
| +26% | +$484K | 0.17% | 122 |
|
|
2020
Q4 | $1.63M | Hold |
9,631
| – | – | 0.12% | 140 |
|
|
2020
Q3 | $1.43M | Hold |
9,631
| – | – | 0.12% | 136 |
|
|
2020
Q2 | $1.58M | Sell |
9,631
-238
| -2% | -$36.5K | 0.15% | 126 |
|
|
2020
Q1 | $1.37M | Hold |
9,869
| – | – | 0.15% | 124 |
|
|
2019
Q4 | $1.3M | Sell |
9,869
-1,370
| -12% | -$159K | 0.13% | 134 |
|
|
2019
Q3 | $1.26M | Buy |
11,239
+570
| +5% | +$63.5K | 0.13% | 128 |
|
|
2019
Q2 | $1.18M | Hold |
10,669
| – | – | 0.13% | 138 |
|
|
2019
Q1 | $1.39M | Sell |
10,669
-52
| -0.5% | -$6.32K | 0.16% | 129 |
|
|
2018
Q4 | $1.24M | Hold |
10,721
| – | – | 0.16% | 126 |
|
|
2018
Q3 | $1.15M | Sell |
10,721
-100
| -0.9% | -$10K | 0.13% | 147 |
|
|
2018
Q2 | $923K | Buy |
+10,821
| New | +$889K | 0.12% | 144 |
|
Other funds holding LLY
Equitable Trust's LLY Position: Q2 2026 in Review
Equitable Trust increased its Eli Lilly (LLY) stake by 19% in Q2 2026, buying an estimated $1.92M and bringing the position to 11,841 shares worth $14.2M. The position accounts for 0.59% of the portfolio, ranked #40.
Equitable Trust first reported a position in LLY in Q2 2018 and has held it in 33 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Equitable Trust held 11,841 shares of Eli Lilly worth $14.2M as of Q2 2026.
- Equitable Trust bought 1,879 Eli Lilly shares in Q2 2026, an estimated $1.92M.
- Eli Lilly made up 0.59% of Equitable Trust's portfolio in Q2 2026, its #40 holding.
- Equitable Trust first reported a position in Eli Lilly in Q2 2018 and has held it in 33 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Equitable Trust's 13F filing for Q2 2026, filed 23 Jul 2026.